InnovaBurn is claimed to be the first placental-derived medical device for the management of burns, complex surgical wounds, and hard-to-heal wounds
InnovaBurn is a placental-derived treatment for wounds and burns. (Credit: PRNewswire/ConvaTec)
Convatec has secured clearance from the US Food and Drug Administration (FDA) for its InnovaBurn placental extracellular matrix medical (ECM) device to be used for managing surgical wounds and burns.
The British medical device company designed the InnovaBurn device for the management of burns, complex surgical wounds, hard-to-heal wounds, and partial-thickness second-degree burns.
Available commercially in the US, the device joins the firm’s InnovaMatrix platform as the first and only placental-derived treatment.
Made using Convatec’s proprietary TriCleanse Process, InnovaMatrix products like InnovaBurn ECM provide doctors with a next-generation device that preserves the placenta’s inherent benefits.
The InnovaMatrix products also offer dependability, reproducibility, and safety of a medical device, the medical device company claimed.
Convatec US burn division sales director Debra Noble said: “InnovaBurn is an innovative advancement in ECM technology for patients with partial-thickness, second-degree burns.
“InnovaBurn allows burn patients the benefits of the latest and best placental ECM technology. Our unique source material helps us to manufacture some of the largest ECM sizes in the industry much more affordably, so more patients have access to this brand new technology.
“Physicians tell us they appreciate the special sizing and InnovaBurn’s ease of use that help them manage larger wounds like burns.”
InnovaBurn is a xenograft controlled for genetic variability, as well as environmental and lifestyle aspects like food and activity levels.
It can also be used for traumatic lacerations, dehisced incisional wounds, pressure and venous ulcers, post-surgical incisions, post-Mohs surgical wounds, and diabetic ulcers, Convatec added.
According to the British firm, treatment with the device does not need preparation, no specific placement orientation, no tracking of tissues, or any special storage. It fits to the wound location and sticks to it.
The patented TriCleanse Placental Extracellular Matrix Process decellularises the ECM, cleans the tissue, and deactivates viruses while preserving the ECM’s structural proteins to support healing.
This method generates a clean, efficient matrix for host cells to bridge across and restructure the defect, Convatec said.